Full notification fileGeneral informationNotification NumberB/FR/13/GT02Member State to which the notification was sentFranceDate of acknowledgement from the Member State Competent Authority25/04/2013Title of the ProjectA phase I/II, open‐label, study of intracerebral administration of adeno‐associated viral vector containing the human alpha‐N‐acetylglucosaminidase gene for the treatment of Sanfilippo type B syndromeProposed period of release:01/04/2013 to 30/09/2013Name of the Institute(s) or Company(ies)Institut Pasteur, ;
3. Is the same GMO release planned elsewhere in the Community?NoHas the same GMO been notified elsewhere by the same notifier?NoGMO characterizationGMO is a:DNA VirusIdentity of the GMO:AAV2.5‐hNaGlu is an Adeno‐Associated Virus serotypes 2 and 5 carrying the human alpha‐N‐acetylglucosaminidase gene.
Family: ParvoviridaeInformation relating to the recipient or parental organisms from wich the GMO is derived
European Commission administrative informationConsent given by the Member State Competent Authority:Not known
|Adeno-associated virus||Dependovirus||Adeno‐Associated Virus||Parvoviridae/Parvoviriae||N/A||N/A|